SCHEMBL2453368

SCHEMBL2453368

N#CCc1cc(Cl)cc2cc(C(=O)O)[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.44
F3 P13726 1/20 0.44
GRIN1 Q05586 2/20 0.38
HPGD P15428 3/20 0.38
DAO P14920 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HRH4 Q9H3N8 6/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258615 0.84 XDH (0.45) HRH4CYP1A2ALOX15
SCHEMBL2452679 0.82 ALOX15 (0.50) HPGDALDH1A1KDM4ELMNAMEN1
SCHEMBL2450985 0.79 HSD17B10 (0.53) F7F3HPGDDAOALDH1A1
SCHEMBL3252857 0.77 F7 (0.44) F7F3GRIN1HPGDDAO
SCHEMBL3274871 0.75 HRH4 (0.56) F7F3GRIN1HPGDDAO
SCHEMBL4154967 0.72 HRH4 (0.59) F7F3GRIN1HPGDDAO
SCHEMBL17865579 0.72 HRH4 (0.58) F7F3GRIN1HPGDDAO
SCHEMBL22396281 0.72 HRH4 (0.59) F7F3GRIN1HPGDDAO
SCHEMBL16571188 0.71 FBP1 (0.40) F7F3HPGDDAOALDH1A1
SCHEMBL3252738 0.71 HRH4 (0.53) ALDH1A1KDM4EHRH4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202993-B2 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202993-B2 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8202993-B2 5-bromo-1'-[(6-bromo-1H-indol-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMANN-LA ROCHE INC. (US) 2012-06-19 US disclosed
US-8076360-B2 e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMAN-LA ROCHE INC. (US) 2011-12-13 US disclosed
US-8076360-B2 e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMAN-LA ROCHE INC. (US) 2011-12-13 US disclosed
US-8076360-B2 e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMAN-LA ROCHE INC. (US) 2011-12-13 US disclosed
US-8071622-B2 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMAN-LA ROCHE INC. (US) 2011-12-06 US disclosed
EP-2102186-B1 INDOLES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
EP-2102186-B1 INDOLES HOFFMANN LA ROCHE (CH) 2011-10-05 EP disclosed
US-8026259-B2 e.g. {5-Chloro-2-[4-(2-oxo-2,3-dihydro-benzooxazol-7-yl)-piperidine-1-carbonyl]-1H-indol-7-yl}-acetonitrile; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, obsessive compulsive disorder HOFFMANN-LA ROCHE INC. (US) 2011-09-27 US disclosed
WO-2008068185-A1 SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
WO-2008068185-A1 SPIRO-PIPERIDINE DERIVATIVES AS VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
US-20080139550-A1 INDOLES HOFFMANN-LA ROCHE INC. 2008-06-12 US disclosed
US-20080139550-A1 INDOLES HOFFMANN-LA ROCHE INC. 2008-06-12 US disclosed
US-20080139550-A1 INDOLES HOFFMANN-LA ROCHE INC. 2008-06-12 US disclosed
US-20080139618-A1 INDOLES HOFFMAN-LA ROCHE INC. 2008-06-12 US disclosed
WO-2008068183-A1 INDOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
US-20080139554-A1 SPIRO-PIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2008-06-12 US disclosed
WO-2008068183-A1 INDOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
US-20080139549-A1 INDOLES HOFFMANN-LA ROCHE INC. 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139554-A1 SPIRO-PIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 F7 4227/4885F3 3367/4885GRIN1 197/4885
US-20080139550-A1 INDOLES HTR1A, AVPR1A, HTR4 F7 4232/4885F3 2046/4885GRIN1 214/4885
US-20080139618-A1 INDOLES HTR1A, AVPR1A, TPH1 F7 3929/4885F3 2289/4885GRIN1 203/4885
US-20080139549-A1 INDOLES HTR1A, AVPR1A, HTR4 F7 4200/4885F3 2062/4885GRIN1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.